Search research articles

关于 JoVE

概览领导团队博客 JoVE 帮助中心

作者

出版流程编辑委员会范围与政策同行评审常见问题投稿

图书馆员

用户评价订阅访问资源图书馆顾问委员会常见问题

研究

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments 存档

教育

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual 教师资源中心教师网站

使用条款与条件

相关概念视频

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序

Same author

Single-position ligand modifications tune CB<sub>2</sub>R activity by targeting the toggle switch.

Chemical science·2026

Same author

Preclinical development of [<sup>18</sup>F]TAAR1-2203 as a PET radioligand for imaging TAAR1 expression and receptor occupancy.

European journal of nuclear medicine and molecular imaging·2025

Same author

The Parkinson's Disease Drug Tolcapone and Analogues are Potent Glycomimetic Lectin Inhibitors of Pseudomonas aeruginosa LecA.

Angewandte Chemie (International ed. in English)·2025

Same author

Continuous Hemodynamic Response to Angiotensin II in Critically Ill Pediatric Patients: A Single Center Cohort Study.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG·2025

Same author

Pain, Analgesia, Sedation, and the Developing Brain.

Pediatric clinics of North America·2025

Same author

Pediatric Pharmacy Association 2025 KIDs List of Key Potentially Inappropriate Drugs in Pediatrics.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG·2025

Search research articles

相关实验视频

Updated: Jun 6, 2025

Activation and Measurement of NLRP3 Inflammasome Activity Using IL-1β in Human Monocyte-derived Dendritic Cells

Activation and Measurement of NLRP3 Inflammasome Activity Using IL-1β in Human Monocyte-derived Dendritic Cells

Published on: May 22, 2014

新型宏环NLRP3抑制剂新型宏环NLRP3抑制剂

Stefanie Mesch¹, Jonathan Shannon², David Miller³

¹F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Basel CH-4070, Switzerland.

Journal of medicinal chemistry

|November 25, 2024

概括

研究人员开发了新的宏环NLRP3抑制剂来治疗慢性炎症疾病. 这些抑制剂的性能比前几代更好,为CAPS和痛风性关节炎等疾病提供了新的治疗潜力.

更多相关视频

A Macrophage Reporter Cell Assay to Examine Toll-Like Receptor-Mediated NF-kB/AP-1 Signaling on Adsorbed Protein Layers on Polymeric Surfaces

A Macrophage Reporter Cell Assay to Examine Toll-Like Receptor-Mediated NF-kB/AP-1 Signaling on Adsorbed Protein Layers on Polymeric Surfaces

Published on: January 7, 2020

Detection of Inflammasome Activation and Pyroptotic Cell Death in Murine Bone Marrow-derived Macrophages

Detection of Inflammasome Activation and Pyroptotic Cell Death in Murine Bone Marrow-derived Macrophages

Published on: May 21, 2018

相关实验视频

Last Updated: Jun 6, 2025

Activation and Measurement of NLRP3 Inflammasome Activity Using IL-1β in Human Monocyte-derived Dendritic Cells

Activation and Measurement of NLRP3 Inflammasome Activity Using IL-1β in Human Monocyte-derived Dendritic Cells

Published on: May 22, 2014

A Macrophage Reporter Cell Assay to Examine Toll-Like Receptor-Mediated NF-kB/AP-1 Signaling on Adsorbed Protein Layers on Polymeric Surfaces

A Macrophage Reporter Cell Assay to Examine Toll-Like Receptor-Mediated NF-kB/AP-1 Signaling on Adsorbed Protein Layers on Polymeric Surfaces

Published on: January 7, 2020

Detection of Inflammasome Activation and Pyroptotic Cell Death in Murine Bone Marrow-derived Macrophages

Detection of Inflammasome Activation and Pyroptotic Cell Death in Murine Bone Marrow-derived Macrophages

Published on: May 21, 2018

科学领域:

药用化学医学化学
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

NLRP3炎症酶的异常激活与许多慢性炎症疾病有关,包括冷氨酸相关周期性综合征 (CAPS),神经退行性疾病和痛风性关节炎.
开发NLRP3抑制剂来治疗这些疾病具有显著的治疗兴趣.
第一代抑制剂,如MCC950,通过表型查被确定,其机制后来被阐明.

研究的目的:

发现和优化新型宏环NLRP3抑制剂.
为了解决前几代抑制剂的局限性,例如中等强度和潜在的药物诱导肝损伤.
探索结构-活性关系,从而改善NLRP3抑制.

主要方法:

在优化第二代NLRP3抑制剂的过程中利用了构造性研究.
基于MCC950优化的见解设计和合成了新的宏环化合物.
评估了新开发的宏循环的抑制性质和潜在的治疗应用.

主要成果:

成功设计和优化了一种新的宏环NLRP3抑制剂类别.
这些宏循环代表了新一代NLRP3抑制剂,具有潜在的改善药理特征.
该研究详细介绍了这一有前途的治疗类的发现和优化过程.

结论:

这些宏环NLRP3抑制剂的发现为治疗慢性炎症疾病提供了有前途的新途径.
这一类的进一步发展可能会导致对NLRP3介导疾病的更有效,更安全的治疗方法.
这项工作强调了基于结构的设计在促进炎症酶抑制剂药物发现方面的价值.